N(6)-((dimethylamino)methylene)mitomycin C

mitomycin C analog; structure given in first source

Also Known As:

BMY 25282; BMY-25282; DMA-MMC; Methanimidamide, N'-(8-(((aminocarbonyl)oxy)methyl)-1,1a,2,4,7,8,8a,8b-octahydro-8a-methoxy-5-methyl-4,7-dioxoazirino(2',3':3,4)pyrrolo(1,2-a)indol-6-yl)-N,N-dimethyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))-

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Leukemia 12/01/1985 - "Against P-388 leukemia, however, the efficacy of the drugs was equivalent when BMY-25282 was administered in the pluronic vehicle. "
2.	Neoplasms (Cancer) 12/01/1985 - "In an in vitro clonogenic assay involving freshly explanted human tumors, BMY-25282 was consistently more potent in cytotoxic effects than MMC. " 11/01/1985 - "The non-cross-resistance of the analogue in the model was confirmed in vivo by treating tumor xenograft-bearing athymic mice with equitoxic doses of MMC or BMY 25282. " 11/01/1985 - "In this study we demonstrated that BMY 25282 can overcome MMC resistance in a series of previously described human colon carcinoma cells resistant to MMC (Cancer Res., 44: 5880, 1984). " 07/01/1986 - "A comparison of the cytotoxicity of MC to EMT6 tumor cells with that of the structural analogues porfiromycin (PM), N-(N',N'-dimethylaminomethylene)amine analogue of mitomycin C (BMY-25282), and N-(N',N'-dimethylaminomethylene)amine analogue of porfiromycin (BL-6783) has demonstrated that PM is considerably less cytotoxic to aerobic EMT6 cells than MC, whereas BMY-25282 and BL-6783 are significantly more toxic. "
3.	Carcinoma (Carcinomatosis) 11/01/1985 - "These studies demonstrate that BMY 25282 is able to overcome MMC resistance in a series of human colon carcinoma cells and that IDC formation in the MMC-sensitive or -resistant cells parallels cytotoxicity for both MMC and the analogue." 11/01/1985 - "MMC-sensitive cells contained 3 to 8 times as many IDCs as resistant colon carcinoma cells, while no significant differences in IDCs were found between the MMC-sensitive or -resistant cells incubated with BMY 25282. " 11/01/1985 - "In this study we demonstrated that BMY 25282 can overcome MMC resistance in a series of previously described human colon carcinoma cells resistant to MMC (Cancer Res., 44: 5880, 1984). " 11/01/1985 - "BMY 25282, a newly designed analogue of mitomycin C (MMC), was assessed for its non-cross-resistant cytotoxic and biochemical action against MMC-resistant human colon carcinoma cells. "
4.	Cardiotoxicity 07/01/1987 - "These results indicate that the delayed cardiotoxicity of BMY-25282 is schedule dependent."
5.	Colorectal Neoplasms (Colorectal Cancer) 12/01/1985 - "With human colorectal carcinoma samples, BMY-25282 was 13.8 times more potent than MMC. "

Related Drugs and Biologics

1.	Poloxamer (Poloxamer 407)
2.	Mitomycin (Mitomycin-C)
3.	Porfiromycin
4.	N- 7- (2- (nitrophenyldithio)ethyl)mitomycin C
5.	Dexrazoxane (Zinecard)
6.	Reactive Oxygen Species (Oxygen Radicals)
7.	Iron
8.	Free Radicals
9.	Doxorubicin (Adriamycin)
10.	Dacarbazine (DIC)